CR20180307A - Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer - Google Patents
Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncerInfo
- Publication number
- CR20180307A CR20180307A CR20180307A CR20180307A CR20180307A CR 20180307 A CR20180307 A CR 20180307A CR 20180307 A CR20180307 A CR 20180307A CR 20180307 A CR20180307 A CR 20180307A CR 20180307 A CR20180307 A CR 20180307A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- quinolin
- salts
- ona
- cancer treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos, donde x, R1, R2, R3, R4 y R5 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de compuestos de Fórmula (I) y sales de estos para tratar o prevenir una enfermedad mediada por ATM, incluido el cáncer. Esta memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden compuestos de tipo imidazo[4,5-c]quinolin-2-ona sustituidos y sales farmacéuticamente aceptables de estos; kits que comprenden tales compuestos y sales; métodos de producción de tales compuestos y sales; e intermedios útiles en tal producción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1519406.1A GB201519406D0 (en) | 2015-11-03 | 2015-11-03 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
PCT/EP2016/076412 WO2017076895A1 (en) | 2015-11-03 | 2016-11-02 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20180307A true CR20180307A (es) | 2018-10-05 |
Family
ID=55130605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180307A CR20180307A (es) | 2015-11-03 | 2016-11-02 | Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer |
Country Status (20)
Country | Link |
---|---|
US (1) | US20180318287A1 (es) |
EP (1) | EP3371183A1 (es) |
JP (1) | JP2018536649A (es) |
KR (1) | KR20180070703A (es) |
CN (1) | CN108349971A (es) |
AU (1) | AU2016348546B2 (es) |
BR (1) | BR112018007772A2 (es) |
CA (1) | CA3002608A1 (es) |
CL (1) | CL2018001146A1 (es) |
CO (1) | CO2018003969A2 (es) |
CR (1) | CR20180307A (es) |
GB (1) | GB201519406D0 (es) |
HK (2) | HK1255598A1 (es) |
IL (1) | IL258818A (es) |
MX (1) | MX2018005445A (es) |
PE (1) | PE20181345A1 (es) |
PH (1) | PH12018500958A1 (es) |
RU (1) | RU2018120318A (es) |
SV (1) | SV2018005663A (es) |
WO (1) | WO2017076895A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2019057757A1 (en) | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
EP3849984A4 (en) | 2018-09-14 | 2022-06-01 | Suzhou Zanrong Pharma Limited | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]CINNOLIN-2-ONE SERVING AS SELECTIVE KINASE MODULATORS ATAXIA TELANGIECTASIA (ATM ) MUTEATED AND ASSOCIATED USES |
CA3114646C (en) * | 2018-09-30 | 2022-03-08 | Medshine Discovery Inc. | Quinolino-pyrrolidin-2-one derivatives and application thereof |
JOP20210241A1 (ar) * | 2019-03-05 | 2023-01-30 | Astrazeneca Ab | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان |
WO2021098734A1 (zh) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
WO2022128833A1 (en) | 2020-12-15 | 2022-06-23 | Merck Patent Gmbh | Solid transition metal-ligand complexes |
TW202340189A (zh) * | 2022-01-26 | 2023-10-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有肼基的化合物 |
WO2023200427A1 (en) * | 2022-04-11 | 2023-10-19 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012528829A (ja) * | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | 1H−イミダゾ[4,5−c]キノリノン化合物 |
CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
RS62082B1 (sr) * | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
-
2015
- 2015-11-03 GB GBGB1519406.1A patent/GB201519406D0/en not_active Ceased
-
2016
- 2016-11-02 CR CR20180307A patent/CR20180307A/es unknown
- 2016-11-02 PE PE2018000612A patent/PE20181345A1/es unknown
- 2016-11-02 CN CN201680063688.5A patent/CN108349971A/zh active Pending
- 2016-11-02 CA CA3002608A patent/CA3002608A1/en not_active Abandoned
- 2016-11-02 JP JP2018522026A patent/JP2018536649A/ja not_active Withdrawn
- 2016-11-02 MX MX2018005445A patent/MX2018005445A/es unknown
- 2016-11-02 KR KR1020187015448A patent/KR20180070703A/ko unknown
- 2016-11-02 RU RU2018120318A patent/RU2018120318A/ru not_active Application Discontinuation
- 2016-11-02 BR BR112018007772A patent/BR112018007772A2/pt not_active Application Discontinuation
- 2016-11-02 AU AU2016348546A patent/AU2016348546B2/en not_active Ceased
- 2016-11-02 EP EP16790601.5A patent/EP3371183A1/en not_active Withdrawn
- 2016-11-02 US US15/772,118 patent/US20180318287A1/en not_active Abandoned
- 2016-11-02 WO PCT/EP2016/076412 patent/WO2017076895A1/en active Application Filing
-
2018
- 2018-04-06 SV SV2018005663A patent/SV2018005663A/es unknown
- 2018-04-13 CO CONC2018/0003969A patent/CO2018003969A2/es unknown
- 2018-04-22 IL IL258818A patent/IL258818A/en unknown
- 2018-04-30 CL CL2018001146A patent/CL2018001146A1/es unknown
- 2018-05-03 PH PH12018500958A patent/PH12018500958A1/en unknown
- 2018-11-19 HK HK18114727.1A patent/HK1255598A1/zh unknown
-
2019
- 2019-01-03 HK HK19100042.7A patent/HK1257678A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN108349971A (zh) | 2018-07-31 |
HK1257678A1 (zh) | 2019-10-25 |
CL2018001146A1 (es) | 2018-09-04 |
PH12018500958A1 (en) | 2018-11-19 |
CO2018003969A2 (es) | 2018-07-10 |
GB201519406D0 (en) | 2015-12-16 |
IL258818A (en) | 2018-06-28 |
RU2018120318A3 (es) | 2019-12-24 |
MX2018005445A (es) | 2018-08-14 |
AU2016348546B2 (en) | 2019-05-02 |
RU2018120318A (ru) | 2019-12-05 |
EP3371183A1 (en) | 2018-09-12 |
SV2018005663A (es) | 2018-07-20 |
JP2018536649A (ja) | 2018-12-13 |
PE20181345A1 (es) | 2018-08-22 |
AU2016348546A1 (en) | 2018-06-14 |
CA3002608A1 (en) | 2017-05-11 |
KR20180070703A (ko) | 2018-06-26 |
US20180318287A1 (en) | 2018-11-08 |
WO2017076895A1 (en) | 2017-05-11 |
BR112018007772A2 (pt) | 2018-10-30 |
HK1255598A1 (zh) | 2019-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
CO2017011969A2 (es) | Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |